Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT802 in Refractory Generalized Myasthenia Gravis
NCT07917923Phase 1Not yet recruiting
- Sponsor
- Daishi Tian
- Start
- Dec 2026
- Primary completion
- Dec 2031
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GT802 in generalized myasthenia gravis (gMG), sponsored by Daishi Tian. Primary endpoint: Adverse Events at 1 year. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
GT802
03
Conditions
generalized myasthenia gravis (gMG)
Beyond the preview
Go deeper on NCT07917923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07917923.